Beta-lactam antibiotics in continuous infusion in critically ill patients by Jeurissen, Axel & Rutsaert, Robert
We read with great interest Taccone and colleagues’ 
article [1], published in a recent issue of Critical Care, on 
the insuﬃ     cient β-lactam concentrations in the early 
phase of severe sepsis and septic shock. While we fully 
agree with the authors’ ﬁ  ndings, we would like to oﬀ  er 
some remarks.
Only 18 of their 80 patients (22.5%) were infected with 
Pseudomonas aeruginosa, but Taccone and colleagues 
used the European Committee on Antimicrobial Suscep-
tibility Testing (EUCAST) minimal inhibitory concen-
tration (MIC) breakpoints of P. aeruginosa to calculate 
the target pharmacokinetics (PK) proﬁ  le  in  all of the 
patients. Because Enterobacteriaceae form a substantial 
part of infectious organisms in intensive care patients, it 
would be interesting to see how many patients would 
attain the PK proﬁ  le for these microorganisms [2]. For 
cefepime, for instance, if the EUCAST sensitivity thres-
hold of 1 mg/L were used, 17 of 19 patients (89%) would 
attain the target PK proﬁ  le as compared with 3 of 19 
patients (16%) for P. aeruginosa. Of course, we agree that, 
in an empirically started antibiotic regimen, the organ-
isms, let alone the MIC, are not known to the clinician.
Furthermore, the data of Taccone and colleagues 
should be interpreted in light of local epidemiology and 
resistance data. In a Belgian multicenter study, all 
P. aeruginosa strains isolated from patients hospitalized 
in the intensive care unit (ICU) had an MIC90 (MIC 
required to inhibit the growth of 90% of organisms) for 
meropenem of 0.12 mg/L [3]. With this MIC, even more 
than 75% of the patients would have attained the target 
PK proﬁ  le. In addition, we think that the initial loading 
dose should be followed immediately by an extended or 
continuous infusion in order to obtain an optimal PK/
pharmacodynamics (PK/PD) proﬁ  le [4].
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We thank Jeurissen and Rutsaert for their interest in our 
study [1] and would like to reply to the important points 
they raise. In our patient population, one third of docu-
mented infections were due to P. aeruginosa as micro-
biological samples remained negative in 30% of patients 
with sepsis. Indeed, P. aeruginosa is frequently isolated in 
patients with comorbid illnesses or indwelling catheters 
or who are on mechanical ventilation or under  going 
surgery, all of these conditions being typical in ICU 
patients [5]. Pseudomonas infections are associated with 
the highest mortality rate in this ICU patient population. 
For all of these reasons, it seems logical to develop an 
empirical strategy that targets this pathogen in patients 
with nosocomial infections.
We agree that in vitro studies on Pseudomonas suscep-
tibility may show MICs that are much lower than the 
upper threshold of sensibility proposed by the EUCAST 
for carbapenems. However, in all epidemiologic studies, 
only the ﬁ  rst isolated strain of P. aeruginosa is considered 
for MIC determination. Besides having an intrinsic 
resistance to a wide range of antimicrobials, Pseudo mo nas 
is able to acquire resistance via several mechanisms or 
under antimicrobial pressure. A recent study showed that 
Pseudomonas strains isolated from ICU patients are able 
to progressively increase the in vitro MIC level to
diﬀ  erent antibiotics during therapy [6].
Finally, we agree that the extended or continuous infu-
sion of β-lactams can optimize the PK/PD proﬁ  le of these 
drugs. Unfortunately, as only retrospective studies have 
provided evidence in favor of continuous infusion over 
intermittent infusion (especially in pathogens with higher 
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© 2010 BioMed Central LtdMICs and in ventilator-associated pneumonia [7]), a pros-
pective study in this setting is warranted.
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